Telsey Advisory Group Maintains Outperform on Holley, Lowers Price Target to $5.5
Trade with 70% Backtested Accuracy
Analyst Views on HLLY
About HLLY
About the author
Cytokinetics Faces Shareholder Claims Over Executive Misconduct, Potential for Corporate Reforms
- Shareholder Claims Investigation: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders who purchased shares before December 27, 2023, to seek corporate reforms and fund recovery.
- FDA Review Delays: Cytokinetics acknowledged in May 2025 that it failed to include a Risk Evaluation and Mitigation Strategy in its New Drug Application, resulting in the FDA extending the review date from September 2025 to December 2025, which negatively impacted the company's reputation and shareholder confidence.
- False Statement Allegations: A federal securities fraud class action alleges that Cytokinetics' executives made misleading statements that caused significant harm to shareholders, potentially affecting the company's future financing capabilities.
- Legal Consequences: Shareholders who purchased shares before December 27, 2023, can seek court-approved incentive awards, highlighting potential flaws in corporate governance and legal risks.
Holley Inc. Faces Shareholder Lawsuit Over Securities Fraud Allegations
- Shareholder Lawsuit Initiated: Current shareholders of Holley Inc. (NYSE: HLLY) can seek corporate reforms and fund returns, indicating significant legal challenges that may impact shareholder confidence and market performance.
- Fraud Allegations Survive: A federal securities fraud class action has survived a motion to dismiss, alleging that Holley executives failed to disclose deteriorating relationships with distributors, which could lead to declining sales and affect future revenues.
- Market Trust Crisis: Holley's excessive focus on its direct-to-consumer channel has damaged relationships with distributors, which are crucial for revenue, potentially resulting in market share loss and diminished competitive standing.
- Consequences of Integration Failure: Holley has failed to effectively integrate its acquisitions, leading to operational inefficiencies and inventory management issues, which exacerbate financial pressures and could hinder the company's long-term strategic growth.
Canaccord Genuity Keeps Buy Rating on Holley and Increases Price Target to $7
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
Telsey Advisory Group Keeps Outperform Rating on Holley and Increases Price Target to $5
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve their trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools they need to succeed in the stock market every day.
Holley projects 2025 revenue between $590M and $605M, focusing on margin growth and debt reduction.
Management Insights: Holley Inc. reported a strong Q3 2025 with a 6.4% core business growth, emphasizing their omnichannel strategy and significant progress in B2B channels, alongside improved free cash flow and reduced debt leverage.
Financial Performance: The company achieved net sales of $138.4 million, a gross margin of 43.2%, and an adjusted EBITDA margin of 19.6%, marking improvements in profitability and operational metrics compared to the previous year.
Updated Guidance: Management raised revenue expectations for 2025 to a range of $590 million to $605 million, reflecting increased confidence in their ability to navigate macroeconomic conditions and sustain growth.
Risks and Concerns: Ongoing risks include inflation and macroeconomic uncertainty, with analysts expressing caution regarding potential sales deceleration and inventory management, while management remains focused on operational discipline and strategic execution.
Holley Performance Brands Reduces Debt by $100 Million in Two Years
Debt Reduction Announcement: Holley Performance Brands has proactively reduced its debt by an additional $10 million, totaling $100 million in repayments since September 2023, reflecting a commitment to strengthen its balance sheet and enhance financial flexibility.
Positive Financial Outlook: The company's CFO, Jesse Weaver, emphasized that the debt repayment demonstrates the effectiveness of their transformation strategy, highlighting disciplined operations and strong cash flow generation.
Interest Savings: Holley anticipates that these debt prepayments will result in up to $4 million in annualized net interest savings, further contributing to their financial health.
Company Overview: Holley Performance Brands specializes in high-performance automotive products and is known for its innovative approach and strategic acquisitions, aiming to enhance the enthusiast experience and drive growth in the automotive aftermarket industry.
Cytokinetics Faces Shareholder Claims Over Executive Misconduct, Potential for Corporate Reforms
- Shareholder Claims Investigation: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders who purchased shares before December 27, 2023, to seek corporate reforms and fund recovery.
- FDA Review Delays: Cytokinetics acknowledged in May 2025 that it failed to include a Risk Evaluation and Mitigation Strategy in its New Drug Application, resulting in the FDA extending the review date from September 2025 to December 2025, which negatively impacted the company's reputation and shareholder confidence.
- False Statement Allegations: A federal securities fraud class action alleges that Cytokinetics' executives made misleading statements that caused significant harm to shareholders, potentially affecting the company's future financing capabilities.
- Legal Consequences: Shareholders who purchased shares before December 27, 2023, can seek court-approved incentive awards, highlighting potential flaws in corporate governance and legal risks.
Holley Inc. Faces Shareholder Lawsuit Over Securities Fraud Allegations
- Shareholder Lawsuit Initiated: Current shareholders of Holley Inc. (NYSE: HLLY) can seek corporate reforms and fund returns, indicating significant legal challenges that may impact shareholder confidence and market performance.
- Fraud Allegations Survive: A federal securities fraud class action has survived a motion to dismiss, alleging that Holley executives failed to disclose deteriorating relationships with distributors, which could lead to declining sales and affect future revenues.
- Market Trust Crisis: Holley's excessive focus on its direct-to-consumer channel has damaged relationships with distributors, which are crucial for revenue, potentially resulting in market share loss and diminished competitive standing.
- Consequences of Integration Failure: Holley has failed to effectively integrate its acquisitions, leading to operational inefficiencies and inventory management issues, which exacerbate financial pressures and could hinder the company's long-term strategic growth.
Canaccord Genuity Keeps Buy Rating on Holley and Increases Price Target to $7
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
Telsey Advisory Group Keeps Outperform Rating on Holley and Increases Price Target to $5
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them make informed decisions.
Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies to improve their trading outcomes.
Market Winning Tools: The platform is designed to equip traders with the tools they need to succeed in the stock market every day.
Holley projects 2025 revenue between $590M and $605M, focusing on margin growth and debt reduction.
Management Insights: Holley Inc. reported a strong Q3 2025 with a 6.4% core business growth, emphasizing their omnichannel strategy and significant progress in B2B channels, alongside improved free cash flow and reduced debt leverage.
Financial Performance: The company achieved net sales of $138.4 million, a gross margin of 43.2%, and an adjusted EBITDA margin of 19.6%, marking improvements in profitability and operational metrics compared to the previous year.
Updated Guidance: Management raised revenue expectations for 2025 to a range of $590 million to $605 million, reflecting increased confidence in their ability to navigate macroeconomic conditions and sustain growth.
Risks and Concerns: Ongoing risks include inflation and macroeconomic uncertainty, with analysts expressing caution regarding potential sales deceleration and inventory management, while management remains focused on operational discipline and strategic execution.
Holley Performance Brands Reduces Debt by $100 Million in Two Years
Debt Reduction Announcement: Holley Performance Brands has proactively reduced its debt by an additional $10 million, totaling $100 million in repayments since September 2023, reflecting a commitment to strengthen its balance sheet and enhance financial flexibility.
Positive Financial Outlook: The company's CFO, Jesse Weaver, emphasized that the debt repayment demonstrates the effectiveness of their transformation strategy, highlighting disciplined operations and strong cash flow generation.
Interest Savings: Holley anticipates that these debt prepayments will result in up to $4 million in annualized net interest savings, further contributing to their financial health.
Company Overview: Holley Performance Brands specializes in high-performance automotive products and is known for its innovative approach and strategic acquisitions, aiming to enhance the enthusiast experience and drive growth in the automotive aftermarket industry.
